New ad campaign drives double digit growth for Kerasal Foot Ointment

After implementation of new marketing programs, retail sales of Kerasal Exfoliating Foot Ointment grew at over 14% last 3 months compared to the same period last year.

Retail sales of Kerasal Exfoliating Foot Ointment last 3 months grew at over 14% compared to the same period last year, outpacing the foot medication category’s growth of only 1.3% (Source: Symphony IRI, 12 week period ending February 24, 2013).  Kerasal Foot Ointment is a clinically proven topical formula and one-step solution for exfoliating and moisturizing dry feet. Kerasal Foot Ointment is recommended by podiatrists and approved by the American Podiatric Medical Association. The company believes new advertising programs and strong recommendations from podiatrists are contributing to consumer sales.  The U.S. team launches a new ad campaign, including new television commercial in June for the summer foot care season.

About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 35 countries. The company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail® and Kaprolac®. Kerasal Nail® (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.se

About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit: www.mobergpharma.com.

Contacts

Subscribe